[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100569213":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":20,"locations":29,"responsibleParty":47,"collaborators":10,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":10,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":10,"studyType":63,"phases":10,"briefSummary":64,"conditions":65,"keywords":68,"overallStatus":31,"whyStopped":10,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Instituto Nacional de Enfermedades Respiratorias","OTHER_GOV",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"TMP\u002FSMZ (Control)",null,"Patients with HIV and PCP starting treatment with trimethoprim\u002Fsulfamethoxazole (TMP\u002FSMZ).",{"label":13,"type":10,"description":14,"interventionNames":10},"Caspo (Study)","Patients with HIV and PCP starting treatment with caspofungin with or without clindamycin or primaquine; or switching from trimethoprim\u002Fsulfamethoxazole to caspofungin before day 7 of treatment initiation.",[16],{"name":17,"affiliation":18,"role":19},"Santiago Avila, PhD","Center for Research in Infectious Diseases (CIENI)","PRINCIPAL_INVESTIGATOR",[21,26],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Xavier Flores, MD","CONTACT","(+52 55) 5940 2110","xavier.flores@cieni.org.mx",{"name":22,"role":23,"phone":27,"phoneExt":28,"email":25},"(+52 55) 5666 7985","164",[30],{"facility":18,"status":31,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"RECRUITING","Mexico City","Tlalpan","14080","Mexico","MX",{"type":38,"coordinates":39},"Point",[40,41],-99.12766,19.42847,{"lat":41,"lon":40},[44,46],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":45},"xavier.flores@cieni.org",{"name":22,"role":23,"phone":27,"phoneExt":28,"email":45},{"type":19,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Santiago Avila-Rios","Head of the Center for Research in Infectious Diseases.","100569213","caspofungin-for-pneumocystis-pneumonia-in-plwhiv-100569213",false,"NCT06691321","Caspofungin for Pneumocystis Pneumonia in PLWHIV.","Efficacy of Caspofungin for Pneumocystis Jirovecii Pneumonia in People Living With HIV\u002FAIDS.","Inclusion Criteria:\n\n* Diagnosis of probable or proven PCP, according to its diagnostic classification (refer to classification at the end of this section).\n* Have clinical laboratory and virological diagnostic laboratory studies at the time of admission.\n\n  * Classification criteria for Pneumonia by P. jirovecii according to Robert-Gangneux et al.:\n\nProven: Confirmation by pathology or microbiology. Possible: Presence of three out of four clinical or radiological criteria. Probable: Presence of one clinical or radiological criterion without another identified microorganism.\n\nExclusion Criteria:\n\n* With a treatment switch to caspofungin after day 7 of treatment initiation (applies only to group B).\n* Patients who have developed an additional opportunistic lung infection during their hospitalization, other than cytomegalovirus pneumonitis or SARS-CoV-2 pneumonia.","ALL","18 Years","60 Years",{"count":61,"type":62},60,"ESTIMATED","OBSERVATIONAL","Pneumocystis jirovecii pneumonia is a significant concern in peaple with HIV\u002FAIDS, often severe and potentially fatal. While trimethoprim\u002Fsulfamethoxazole remains the primary treatment, safety concerns exist with alternative options. Research on Pneumocystis jirovecii's beta-D glucan composition has prompted investigations into echinocandins like caspofungin, showing promise in murine models and some positive results in human studies. Evaluating caspofungin's efficacy through observational studies is crucial due to safety advantages over current treatments and limited documented data.",[66,67],"HIV-1-infection","Pneumocystis Pneumonia",[69,70,71],"Pneumocystis jirovecii pneumonia","Echinocandins","Caspofungin","2024-11-15",{"date":74,"type":75},"2024-11-19","ACTUAL",{"date":77,"type":75},"2023-08-01",{"date":79,"type":62},"2025-09-01",{"name":5,"class":6},1]